PMID- 18471962
OWN - NLM
STAT- MEDLINE
DCOM- 20081014
LR  - 20131121
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 268
IP  - 2
DP  - 2008 Sep 18
TI  - Decreased production of vascular endothelial growth factor in 
      adriamycin-resistant breast cancer cells.
PG  - 225-32
LID - 10.1016/j.canlet.2008.03.050 [doi]
AB  - MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, have 
      acquired resistance to several anti-cancer chemotherapeutic agents, such as 
      anthracyclines and taxol. Here, we found that MCF-7/ADR cells produced lower 
      levels of vascular endothelial growth factor (VEGF) than control MCF-7 cells. 
      Molecular analyses using Western blots and reporter constructs containing either 
      the human VEGF promoter or a minimal promoter for the transcription factor, 
      hypoxia-inducible factor-1 (HIF-1), supported the involvement of HIF-1alpha in 
      the down-regulation of VEGF transcription in MCF-7/ADR cells. In addition, the 
      basal activities of Akt and GSK-3beta were deregulated in MCF-7/ADR cells, and 
      either the activation of PI3-kinase or the inhibition of GSK-3 restored the 
      diminished transcription of VEGF. Chick chorioallantoic membrane (CAM) assay 
      finally confirmed that angiogenesis intensity in MCF-7/ADR cells was 
      significantly decreased compared with that in control MCF-7 cells.
FAU - Kim, Jung-Ae
AU  - Kim JA
AD  - College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
FAU - Cho, Kyoung Bin
AU  - Cho KB
FAU - Kim, Mi Ra
AU  - Kim MR
FAU - Park, Byung Chul
AU  - Park BC
FAU - Kim, Sang Kyum
AU  - Kim SK
FAU - Lee, Moo Yeol
AU  - Lee MY
FAU - Kang, Keon Wook
AU  - Kang KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080508
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
MH  - Antibiotics, Antineoplastic/*pharmacology
MH  - Breast Neoplasms/blood supply/*drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Doxorubicin/*pharmacology
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/physiology
MH  - Neovascularization, Pathologic/prevention & control
MH  - Phosphatidylinositol 3-Kinases/physiology
MH  - Promoter Regions, Genetic
MH  - Vascular Endothelial Growth Factor A/*biosynthesis/genetics
EDAT- 2008/05/13 09:00
MHDA- 2008/10/15 09:00
CRDT- 2008/05/13 09:00
PHST- 2008/01/21 00:00 [received]
PHST- 2008/03/27 00:00 [revised]
PHST- 2008/03/28 00:00 [accepted]
PHST- 2008/05/13 09:00 [pubmed]
PHST- 2008/10/15 09:00 [medline]
PHST- 2008/05/13 09:00 [entrez]
AID - S0304-3835(08)00258-9 [pii]
AID - 10.1016/j.canlet.2008.03.050 [doi]
PST - ppublish
SO  - Cancer Lett. 2008 Sep 18;268(2):225-32. doi: 10.1016/j.canlet.2008.03.050. Epub 
      2008 May 8.